Evidence map›Paper›PMID 33335929›Full record

ArticleJournal of immunology research2020

Human Bone Marrow Mesenchymal Stem/Stromal Cells Exposed to an Inflammatory Environment Increase the Expression of ICAM-1 and Release Microvesicles Enriched in This Adhesive Molecule: Analysis of the Participation of TNF-

Juan J Montesinos, Lucero López-García, Víctor A Cortés-Morales, Lourdes Arriaga-Pizano, Ricardo Valle-Ríos, Guadalupe R Fajardo-Orduña, Marta E Castro-Manrreza

Open access · goldAbstract read
In one paragraph

Article in Journal of immunology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Cell-based therapies for rheumatoid arthritis: opportunities and challenges.Therapeutic advances in musculoskeletal disease · 2022
    Review
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Juan J MontesinosMesenchymal Stem Cells Laboratory, Oncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City C.P. 06720, Mexico.
Lucero López-GarcíaImmunology and Stem Cells Laboratory, FES Zaragoza, National Autonomous University of Mexico (UNAM), Mexico City C.P. 09230, Mexico.
Víctor A Cortés-MoralesMesenchymal Stem Cells Laboratory, Oncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City C.P. 06720, Mexico.
Lourdes Arriaga-PizanoMedical Research Unit in Immunochemistry, Specialty Hospital, National Medical Center (IMSS), Mexico City C.P. 06720, Mexico.
Ricardo Valle-RíosPeripheral Unit for Research in Cancer and Immunology, Research Division, Faculty of Medicine, UNAM, Mexico City C.P. 04360, Mexico.
Guadalupe R Fajardo-OrduñaMesenchymal Stem Cells Laboratory, Oncology Research Unit, Oncology Hospital, National Medical Center (IMSS), Mexico City C.P. 06720, Mexico.
Marta E Castro-ManrrezaImmunology and Stem Cells Laboratory, FES Zaragoza, National Autonomous University of Mexico (UNAM), Mexico City C.P. 09230, Mexico.ORCID https://orcid.org/0000-0002-7098-9905
Mexican Social Security Institute · MXUniversidad Nacional Autónoma de México · MXHospital Infantil de México Federico Gómez · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone marrow mesenchymal stem/stromal cells (BM-MSCs) have immunoregulatory capacity; therefore, they have been used in different clinical protocols in which it is necessary to decrease the immune response. This capacity is mainly regulated by TNF-

Indexed as

Cellular MicroenvironmentBiomarkersCell Adhesion MoleculesCell-Derived MicroparticlesCytokinesDisease SusceptibilityHistocompatibility Antigens Class IHumansImmunophenotypingInflammationInflammation MediatorsIntercellular Adhesion Molecule-1Interferon-gammaLeukocytes, MononuclearMesenchymal Stem CellsModels, BiologicalBiomarkersCell Adhesion MoleculesCytokinesHistocompatibility Antigens Class IICAM1 protein, humanInflammation MediatorsIntercellular Adhesion Molecule-1Interferon-gammaTumor Necrosis Factor-alpha

Identifiers

PMID33335929
PMCPMC7723491
OpenAlexW3109672820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.